Genmab — Oktober 2018
-
spændende om vi kan holde dne nedre del af guidance nu
-
de skriver i meddelelsen :"one-time adjustment outside the
U.S. related to accruals for retroactive pricing adjustments which
negatively impacted this worldwide operational growth by 16 percentage
points" -
@Thetreble, hvad mener du med at der er fusket med fase 2 resultaterne?
-
men de 16% point er vist ifht Q3 sidste år - så væksten skulle have heddet 75% ifht Q32017
-
RoW Q3 2017 hed usd 107 mio
-
Enig Thomas. Thetreble, hold dig til facts eller gør det klart at det er dine mavefornemmelser...
-
Direkte latterligt og forkasteligt med indirekte beskyldninger om fisk
-
vi skal nok snart kigge efter en nedjustering af guidance
-
fusk på baggrund af en fornemmelse.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind